|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.936 EUR | +2.76% |
|
-1.63% | -45.54% |
| Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
AB Science S.A. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 0.448 million compared to EUR 0.629 million a year ago. Net loss was EUR 10.41 million compared to EUR 7.14 million a year ago.
Basic loss per share from continuing operations was EUR 0.22 compared to EUR 0.15 a year ago. Diluted loss per share from continuing operations was EUR 0.22 compared to EUR 0.15 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -45.54% | 106M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
AB SCIENCE 
